Amneal Pharmaceuticals' stock soars 14% premarket after company offers upbeat Q1 guidanceMarket Watch • 04/17/23
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial GuidanceBusiness Wire • 04/17/23
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 03/02/23
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mgBusiness Wire • 03/02/23
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 YearsInvestors Business Daily • 01/25/23
Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal's generic products in Europe, Australia and New ZealandGlobeNewsWire • 01/04/23
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag ApprovalBusiness Wire • 12/20/22
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United StatesBusiness Wire • 11/22/22
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson's DiseaseBusiness Wire • 11/11/22
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag EstimatesZacks Investment Research • 11/04/22
Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and RegulatoryBusiness Wire • 10/31/22
Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United StatesBusiness Wire • 10/03/22
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – SpecialtyBusiness Wire • 09/06/22
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson's DiseaseBusiness Wire • 08/31/22